SCYX and POXEL Related Headlines
Go Back- Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
- SCYNEXIS acquires PXL-770 drug for rare kidney disease treatment
- SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
SCYX and POXEL Related Press Releases
Go Back- Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million
- SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
